These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 16683204)
1. Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies. Cho CD; Fisher GA; Halsey J; Sikic BI Invest New Drugs; 2006 Mar; 24(2):117-23. PubMed ID: 16683204 [TBL] [Abstract][Full Text] [Related]
2. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. Kuo T; Cho CD; Halsey J; Wakelee HA; Advani RH; Ford JM; Fisher GA; Sikic BI J Clin Oncol; 2005 Aug; 23(24):5613-9. PubMed ID: 16110021 [TBL] [Abstract][Full Text] [Related]
3. A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. Fisher GA; Kuo T; Ramsey M; Schwartz E; Rouse RV; Cho CD; Halsey J; Sikic BI Clin Cancer Res; 2008 Nov; 14(21):7074-9. PubMed ID: 18981005 [TBL] [Abstract][Full Text] [Related]
4. Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors. Hanauske AR; Cassidy J; Sastre J; Bolling C; Jones RJ; Rakhit A; Fettner S; Brennscheidt U; Feyereislova A; Díaz-Rubio E Clin Cancer Res; 2007 Jan; 13(2 Pt 1):523-31. PubMed ID: 17255274 [TBL] [Abstract][Full Text] [Related]
5. Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO). Hartmann JT; Pintoffl JP; Kröning H; Bokemeyer C; Holtmann M; Höhler T Onkologie; 2008 May; 31(5):237-41. PubMed ID: 18497512 [TBL] [Abstract][Full Text] [Related]
6. Postoperative chemoradiotherapy in gastric cancer: a phase I study of radiotherapy with dose escalation of oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX regimen). Wang X; Wang Y; Qiu M; Li Q; Li ZP; He B; Xu F; Shen YL; Gou HF; Yang Y; Cao D; Yi C; Liu JY; Luo DY; Liao ZY; Bi F Med Oncol; 2011 Dec; 28 Suppl 1():S274-9. PubMed ID: 21116880 [TBL] [Abstract][Full Text] [Related]
7. Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO). Hofheinz RD; Kubicka S; Wollert J; Arnold D; Hochhaus A Onkologie; 2006 Dec; 29(12):563-7. PubMed ID: 17202826 [TBL] [Abstract][Full Text] [Related]
8. Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer. Rosati G; Rossi A; Tucci A; Pizza C; Manzione L Ann Oncol; 2001 May; 12(5):669-74. PubMed ID: 11432626 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Maindrault-Goebel F; de Gramont A; Louvet C; André T; Carola E; Gilles V; Lotz JP; Tournigand C; Mabro M; Molitor JL; Artru P; Izrael V; Krulik M Ann Oncol; 2000 Nov; 11(11):1477-83. PubMed ID: 11142489 [TBL] [Abstract][Full Text] [Related]
10. Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer. Chen E; Jonker D; Gauthier I; MacLean M; Wells J; Powers J; Seymour L Clin Cancer Res; 2009 Feb; 15(4):1481-6. PubMed ID: 19228749 [TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil i.v. bolus every two weeks: a dose finding study in advanced previously treated colorectal carcinoma. Southern Italy Cooperative Oncology Group. Comella P; De Vita F; De Lucia L; Casaretti R; Avallone A; Orditura M; Rivellini F; Palmeri S; Catalano G; Comella G Ann Oncol; 2000 Apr; 11(4):461-8. PubMed ID: 10847467 [TBL] [Abstract][Full Text] [Related]
12. First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. Zampino MG; Magni E; Massacesi C; Zaniboni A; Martignetti A; Zorzino L; Lorizzo K; Santoro L; Boselli S; de Braud F Cancer; 2007 Aug; 110(4):752-8. PubMed ID: 17594712 [TBL] [Abstract][Full Text] [Related]
13. [Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD]. de Gramont A; Tournigand C; Louvet C; André T; Molitor JL; Raymond E; Moreau S; Vignoud J; Le Bail N; Krulik M Rev Med Interne; 1997; 18(10):769-75. PubMed ID: 9500010 [TBL] [Abstract][Full Text] [Related]
14. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ychou M; Conroy T; Seitz JF; Gourgou S; Hua A; Mery-Mignard D; Kramar A Ann Oncol; 2003 Mar; 14(3):481-9. PubMed ID: 12598357 [TBL] [Abstract][Full Text] [Related]
15. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Masi G; Allegrini G; Cupini S; Marcucci L; Cerri E; Brunetti I; Fontana E; Ricci S; Andreuccetti M; Falcone A Ann Oncol; 2004 Dec; 15(12):1766-72. PubMed ID: 15550581 [TBL] [Abstract][Full Text] [Related]
16. Biweekly bolus 5-fluorouracil and leucovorin plus oxaliplatin in pretreated patients with advanced colorectal cancer: a dose-finding study. Yang TS; Chen JS; Tang R; Chiang JM; Hsieh PS; Yeh CY; Changchien CR Anticancer Drugs; 2003 Feb; 14(2):145-51. PubMed ID: 12569301 [TBL] [Abstract][Full Text] [Related]
17. Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Messersmith WA; Jimeno A; Jacene H; Zhao M; Kulesza P; Laheru DA; Kahn Y; Spira A; Dancey J; Iacobuzio-Donahue C; Donehower RC; Carducci M; Rudek MA; Hidalgo M Clin Colorectal Cancer; 2010 Dec; 9(5):297-304. PubMed ID: 21208844 [TBL] [Abstract][Full Text] [Related]
18. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Maindrault-Goebel F; de Gramont A; Louvet C; André T; Carola E; Mabro M; Artru P; Gilles V; Lotz JP; Izrael V; Krulik M; Eur J Cancer; 2001 May; 37(8):1000-5. PubMed ID: 11334725 [TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies. Comella P; Casaretti R; De Rosa V; Avallone A; Izzo F; Fiore F; Lapenta L; Comella G Ann Oncol; 2002 Dec; 13(12):1874-81. PubMed ID: 12453855 [TBL] [Abstract][Full Text] [Related]
20. A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. Lévi F; Zidani R; Brienza S; Dogliotti L; Perpoint B; Rotarski M; Letourneau Y; Llory JF; Chollet P; Le Rol A; Focan C Cancer; 1999 Jun; 85(12):2532-40. PubMed ID: 10375099 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]